$235.00 - $8,140.00

$235.00 - $8.00

Choose an Option...
  • 100 mg - $8,140.00
  • 50 mg - $4,574.00
  • 25 mg - $3,182.00
  • 5 mg - $911.00
  • 1 mg - $235.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ofatumumab, making it ideal for research use. Ofatumumab is a fully human IgG1 monoclonal antibody that specifically targets CD20, a B cell surface antigen expressed from the pre‑B to mature B cell stage but not on plasma cells. CD20 plays a critical role in B cell development, activation, and proliferation. By binding to a unique membrane‑proximal epitope on CD20, Ofatumumab induces B cell depletion through complement‑dependent cytotoxicity (CDC) and antibody‑dependent cellular cytotoxicity (ADCC). This Ofatumumab biosimilar is well suited for studying B cell–mediated diseases, CD20 biology, and the immunologic mechanisms of B cell depletion in autoimmune disease and cancer.

Specifications

Isotype Human IgG1, κ
Recommended Isotype Control(s) RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen Human CD20
Reported Applications In vivo functional assays
in vitro functional assays
Flow cytometry
ELISA
Formulation pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL gel clotting assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Product FAQs